Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878736 | 0.88 | LMNA (0.43) | LMNACHRM3CHRM2SSTR4CHRM4 | |
| SCHEMBL4191418 | 0.86 | CHRM3 (0.51) | CHRM3CHRM2CYP2D6CHRM4CHRM5 | |
| SCHEMBL3216742 | 0.86 | CHRM3 (0.46) | CHRM3CHRM2CYP2D6CHRM4CHRM5 | |
| SCHEMBL4190902 | 0.79 | CHRM3 (0.56) | CHRM3CHRM2CHRM1ALDH1A1 | |
| SCHEMBL4200185 | 0.78 | CHRM3 (0.45) | CHRM3CHRM2SSTR4CHRM4CHRM5 | |
| SCHEMBL4194973 | 0.76 | HTR2C (0.37) | LMNACHRM3CHRM2SSTR4CYP2D6 | |
| SCHEMBL4620005 | 0.74 | ALDH1A1 (0.48) | LMNACHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL3222037 | 0.74 | CHRM2 (0.45) | LMNACHRM3CHRM2CYP2D6CHRM4 | |
| SCHEMBL4620934 | 0.72 | CHRM3 (0.38) | CHRM3CHRM2SSTR4CYP2D6CHRM4 | |
| SCHEMBL4619183 | 0.72 | LMNA (0.53) | LMNASSTR4SLC6A4KIF11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | claimed |
| EP-1797040-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-20 | — | — | EP | claimed |
| WO-2006035303-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | claimed |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| EP-1797040-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035303-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | LMNA 2026/4885CHRM3 1/4885CHRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.